Navigation Links
Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

al achieved the primary endpoint of median Time to Last Unformed Stool (TLUS). Median TLUS for patients treated with prulifloxacin was 32.8 hours which was statistically significant compared to the TLUS for placebo with a p-value of less than 0.0001. Prulifloxacin was generally well tolerated and had a similar safety profile compared to placebo. This is the second of two pivotal Phase 3 clinical studies which will be used to support an NDA submission with the U.S. Food and Drug Administration.
  • Raised $32.9 million in gross proceeds through the sale of 3.3 million shares and warrants to purchase 91,533 shares in a registered direct offering in March 2009.
  • Appointed Francois-Xavier Frapaise, M.D., as Senior Vice President and Chief Scientific Officer and Peter E. Grebow, Ph.D., Executive Vice President of Worldwide Technical Operations at Cephalon, Inc. (Nasdaq: CEPH), to the company's Board of Directors.
  • Published in vitro data highlighting the antibacterial activity of prulifloxacin in the peer-reviewed journal Antimicrobial Agents and Chemotherapy.

  • About Optimer Pharmaceuticals

    Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
    2. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
    3. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
    4. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
    5. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
    6. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
    7. Idenix Pharmaceuticals Reports First Quarter Financial Results
    8. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
    9. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
    10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
    11. Vanda Pharmaceuticals Reports First Quarter 2009 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
    (Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
    (Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
    (Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
    Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
    ... led by Professor Andre Geim, a recipient of the 2010 ... a flow of electrons can magnetise graphene. ... potentially huge breakthrough in the field of spintronics. Spintronics ... spin of the electron, in addition to its fundamental electric ...
    ... IRVINE, Calif., April 15, 2011 CryoLife, Inc. (NYSE: ... and cardiovascular tissue processing company, today announced it has ... of Cardiogenesis Corporation ("Cardiogenesis") to acquire only 49.9 percent ... On April 14, 2011, Cardiogenesis, CryoLife and CryoLife,s wholly-owned ...
    ... Therapeutics, a company that manufactures novel blood plasma-based biomaterials ... on a Series A financing it will use to ... early clinical validation for the Company,s first products. ... Capital Partners, a private investment firm that invests in ...
    Cached Biology Technology:New spin on graphene 2CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 2CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 3CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 4CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 5CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 6CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation 7Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3
    (Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
    (Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
    (Date:11/21/2014)... 2014 C-Labs LLC, a leading provider of ... (IoT), today announced the appointment of John Traynor ... a strategic advisor to the firm, Mr. Traynor will ... is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. Photo ...
    Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
    ... & Science University researchers have identified some of the ... caused by multiple sclerosis (MS), complications of premature birth, ... clues about why the nervous system fails to repair ... of brain damage could be reversed. The research is ...
    ... information can be processed unconsciously when the area of ... temporarily shut down, according to research at Rice University ... Oct. 31 in the Proceedings of the National Academy ... has more than one pathway along which visual information ...
    ... identified some of the key factors that prevent the ... complications of premature birth, and other diseases and conditions. ... system fails to repair itself and suggest ways that ... reversed. The research is published in the August edition ...
    Cached Biology News:Molecular Partners Required For Appropriate Neuronal Gene Repression 2Molecular Partners Required For Appropriate Neuronal Gene Repression 3Molecular Partners Required For Appropriate Neuronal Gene Repression 4Out of sight, out of mind? Not necessarily 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 2OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 3OHSU researchers discover potential mechanism to repair brain damage linked to Multiple Sclerosis 4
    ... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
    ... a synthetic peptide whose sequence is from the C-terminal end of the ... extends from amino acids 429 to 448 of RAR*. The sequence ... - V - S - P - S - S - V ... - Q - S - P - L - L - Q ...
    ... The ELx50 is a fast and versatile ... with our patented Dual-ActionTM 16-channel manifold. This ... the dispense and aspiration manifolds for overfill ... and 384-well formats. The problem of fitting ...
    ... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
    Biology Products: